ClinicalTrials.Veeva

Menu

Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia in Patients With Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass

Cairo University (CU) logo

Cairo University (CU)

Status

Not yet enrolling

Conditions

Induction Anesthesia
Fentanyl
Lidocaine
Ketamine
Coronary Bypass Graft Surgery
Coronary Artery Disease (CAD)
Left Ventricular (LV) Systolic Dysfunction

Treatments

Drug: Fentanyl (IV)
Drug: lidocaine

Study type

Interventional

Funder types

Other

Identifiers

NCT07248202
MD-396-2024

Details and patient eligibility

About

There is no consensus on the ideal induction technique for patients with coronary artery disease and left heart dysfunction. Induction for cardiac surgery focuses on maintaining hemodynamic stability, optimizing myocardial oxygen balance, and minimizing the intubation stress response. Ketamine provides stable hemodynamics in patients with impaired ventricular function, though combining it with opioids to blunt the intubation response may increase post-induction hypotension.

Systemic lidocaine has anesthetic-sparing properties and has been shown to potentiate agents such as thiopentone, propofol, and midazolam. The ketamine-lidocaine combination has also demonstrated favorable hemodynamic effects in septic shock.

This study compares ketamine/fentanyl versus ketamine/lidocaine in term of their impact on cerebral perfusion during CABG. No prior data address these effects, and the goal is to identify the induction regimen that better preserves cerebral oxygenation.

Full description

Upon arrival to the operating room, initial monitoring will include five lead electrocardiograms, non-invasive blood pressure, and pulse oximetry. At the attending anesthetist's discretion, intravenous midazolam will be administered for anxiolytics. Under local anesthesia, an arterial line will be placed in the radial artery of the non-dominant hand and central venous line will be placed in the right internal jugular vein.

Cerebral oximetry monitoring using Near-Infrared Spectroscopy (NIRS) bilaterally (CASMED, Module series Fore-sight Elite, [SN]1931030) will be applied to all patients. After cleansing of the adjacent skin area with alcohol, an adhesive optode pad was placed over each fronto-temporal area. Resting baseline rSO2 values will be obtained after waiting at least 1 min after placement of sensors once values had stabilized. Bispectral index (BIS) will be applied.

The baseline data for the heart rate, systolic, diastolic, and mean systemic arterial pressures will be recorded from the average ward measurement the day before surgery.

in all patients, ketamine will be injected slowly at 1.5 mg/kg in 0.25 mg/kg increments until clinical loss of consciousness. Clinical loss of consciousness (defined as no response to auditory command) will be assessed by asking the patients repeatedly to open their eyes. After loss of consciousness, atracurium 0.5 mg/kg will be administered to facilitate tracheal intubation. Tachycardia and hypertension, (20% increase heart rate, blood pressure from baseline reading) will be managed by a 50 mcg-bolus of Fentanyl. Anesthesia will be maintained by isoflurane (adjusted to maintain end-tidal minimal alveolar concentration of 1-1.2 %) in oxygen/air mixture. Mechanical ventilation will be adjusted to maintain end-tidal CO2 of 35-40 mmHg Any episode of hypotension (defined as mean arterial pressure [MAP] < 70% of the baseline reading and/or MAP <65mmHg, will be managed by 5 mcg norepinephrine (which could be repeated if hypotension persists for 1-min, NE infusion will be started if persisted after 3 boluses). Ephedrine bolus will be give if hypotension was associated with bradycardia.

Enrollment

40 estimated patients

Sex

All

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients with coronary artery disease
  • with moderate to severe left ventricular dysfunction (ejection fraction < 40%),
  • scheduled for elective CABG surgery

Exclusion criteria

  • associated chronic stroke, TIA , carotid occlusive disease( due to abnormal vasomotor activity), patients with known neurological impairment (cerebral infarction , dementia ), significant carotid artery stenosis ,
  • valvular heart disease,
  • persistent arrhythmias,
  • congestive cardiac failure,
  • on mechanical ventilation,
  • intra-aortic balloon pump,
  • emergency surgery,
  • and those with known allergy to any of the study's drugs,
  • severe systemic non-cardiac disease and
  • patients with baseline NIRS reading < 60%
  • Patients with dementia or visual or auditory impairment

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

40 participants in 2 patient groups

fentanyl group
Active Comparator group
Description:
fentanyl bolus during induction of anesthesia
Treatment:
Drug: Fentanyl (IV)
lidocaine group
Active Comparator group
Description:
lidocaine bolus during the induction of anesthesia
Treatment:
Drug: lidocaine

Trial contacts and locations

1

Loading...

Central trial contact

Maha Mostafa

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems